SLC5A2 and diabetes mellitus: Tofogliflozin is a potent and highly selective sodium–glucose cotransporter 2 (SGLT2) inhibitor1, 2, 3, and is currently used for the treatment of patients with type 2 diabetes mellitus in Japan4, 5.